It's only fair to share...
Laroprovstat
CAS 2455427-91-3
MF C20H20F2N6O2 MW414.4 g/mol
1-[6-[[(1S,3S)-3-[[5-(difluoromethoxy)pyrimidin-2-yl]amino]cyclopentyl]amino]-3-pyridinyl]pyridin-2-one
- 1-[6-[[(1S,3S)-3-[[5-(difluoromethoxy)pyrimidin-2-yl]amino]cyclopentyl]amino]pyridin-3-yl]pyridin-2-one
- 6′-(((1S,3S)-3-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)cyclopentyl)amino)-2H-[1,3′-bipyridin]-2-one
- 6′-{[(1S,3S)-3-{[5-(difluoromethoxy)pyrimidin-2-yl]amino}cyclopentyl]amino}-2H-[1,3′-bipyridin]-2-one
6′-{[(1S,3S)-3-{[5-(difluoromethoxy)pyrimidin-2-yl]amino}cyclopentyl]amino}-2H-[1,3′-bipyridin]-2-one
proprotein convertase subtilisin/kexin type 9 (PCSK9), inhibitor, antihyperlipidaemic, 9EEL3YMY29, PCSK9-IN-12, AZD 0780, AZD-0780
- OriginatorDogma Therapeutics
- DeveloperAstraZeneca; Parexel International; Quotient Sciences
- ClassAmines; Antihyperlipidaemics; Cardiovascular therapies; Cyclopentanes; Ethers; Fluorinated hydrocarbons; Hepatoprotectants; Ketones; Pyridines; Pyrimidines; Small molecules; Vascular disorder therapies
- Mechanism of ActionPCSK9 protein inhibitors
- Phase IIIAtherosclerosis; Cardiovascular disorders; Dyslipidaemias; Hyperlipoproteinaemia type II
- Phase ILiver disorders
- 30 Dec 2025AstraZeneca completes a phase I pharmacokinetics trial (In volunteers) in USA (PO) (NCT07216131),
- 10 Nov 2025AstraZeneca initiates enrolment in a phase I pharmacokinetics trial (In volunteers) in USA (PO)(NCT07216131),
- 29 Oct 2025AstraZeneca completes a phase I trial in Dyslipidaemias (Combination therapy) in USA, United Kingdom (PO) (NCT06742853)
SYN
PAT
PAT
- PCSK9 Inhibitors and Methods of Use ThereofPublication Number: US-2020231584-A1Priority Date: 2019-01-18
- Pcsk9 inhibitors and methods of use thereofPublication Number: US-2022220122-A1Priority Date: 2019-01-18
- Pcsk9 inhibitors and methods of use thereofPublication Number: WO-2024013209-A1Priority Date: 2022-07-13
- PCSK9 Inhibitors and Methods of Use ThereofPublication Number: US-2020291041-A1Priority Date: 2019-01-18
- Pcsk9 inhibitors and methods of use thereofPublication Number: WO-2020150473-A2Priority Date: 2019-01-18
- Pcsk9 inhibitors and methods of use thereofPublication Number: WO-2020150474-A1Priority Date: 2019-01-18
- PCSK9 inhibitors and methods of use thereofPublication Number: US-11248001-B2Priority Date: 2019-01-18Grant Date: 2022-02-15
AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
……
/////////laroprovstat, antihyperlipidaemic, 9EEL3YMY29, PCSK9-IN-12, AZD 0780, AZD-0780
It's only fair to share...